目的 探討荷丹膠囊聯(lián)合瑞舒伐他汀鈣治療老年高脂血癥臨床療效。方法 選取2015年6月—2018年6月在航天中心醫(yī)院老年病門診進行治療的100例高脂血癥患者，根據(jù)用藥不同分為治療組（50例）和對照組（50例）。對照組口服瑞舒伐他汀鈣片，10 mg/次，1次/d；治療組在對照組治療基礎上口服荷丹膠囊，4粒/次，3次/d。兩組均連續(xù)治療8周。觀察兩組的臨床療效，比較兩組治療前后血脂指標、血清學指標和氧化應激指標的變化情況。結果 治療后，對照組和治療組的總有效率分別是82%、96%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組總膽固醇（TC）、三酰甘油（TG）、低密度脂蛋白膽固醇（LDL-C）水平均顯著下降，高密度脂蛋白膽固醇（HDL-C）水平均顯著增高，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；治療后，治療組TC、TG、LDL-C水平低于對照組，但HDL-C水平高于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組C反應蛋白（hs-CRP）、嗜酸性粒細胞陽離子蛋白（ECP）、成纖維細胞生長因子21（FGF-21）、攝食抑制因子-1（NSF-1）、瘦素（LEP）、白細胞介素-6（IL-6）、總氧化態(tài)（TOS）水平均較治療前顯著降低，而總抗氧化態(tài)（TAS）水平、對氧磷酶-1（PON1）表達均顯著增高，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；治療后，治療組hs-CRP、ECP、FGF-21、NSF-1、LEP、IL-6、TOS水平明顯低于對照組，而TAS、PON1水平明顯高于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 荷丹膠囊聯(lián)合瑞舒伐他汀鈣治療老年高脂血癥具有較好的臨床療效，可顯著改善患者的血脂指標，降低血清炎性因子水平，改善機體氧化應激狀態(tài)，具有較好的臨床推廣應用價值。

Objective To explore the clinical effect of Hedan Capsules combined with rosuvastatin calcium in treatment of senile hyperlipidemia. Methods 100 Patients with hyperlipidemia in Aerospace Center Hospital from June 2015 to June 2018 were divided into treatment group (50 cases) and control group (50 cases) according to different medication. Patients in the control group were po administered with Rosuvastatin Calcium Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Hedan Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the changes of blood lipid indexes, serological indexes and oxidative stress indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 82% and 96%, and there were differences between two groups (P<0.05). After treatment, TC, TG, and LDL-C in two groups were significantly decreased, but HDL-C was significantly increased, and there were differences in the same group (P<0.05). After treatment, TC, TG, and LDL-C in the treatment group were lower than those in the control group, but HDL-C was higher than that in the control group, and there were differences between two groups (P<0.05). After treatment, hs-CRP, ECP, FGF-21, NSF-1, LEP, IL-6, and TOS in two groups were significantly decreased, but TAS, PON1 were significantly increased, and there were differences in the same group (P<0.05). After treatment, hs-CRP, ECP, FGF-21, NSF-1, LEP, IL-6, and TOS in the treatment group were lower than those in the control group, but TAS and PON1 was higher than that in the control group, and there were differences between two groups (P<0.05). Conclusion Hedan Capsules combined with rosuvastatin calcium has significant clinical effect in treatment of senile hyperlipidemia, and can significantly improve the blood lipid indexes, and also can reduce the level of serum inflammatory factors and improve the oxidative stress state, which has a certain clinical application value.